ELEdvaldo S. Lara

Edvaldo S. Lara

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Edvaldo S. Lara has a total of 40 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Plasmin modulates neutrophilic inflammation and alveolar macrophage function, protecting mice from pneumococcal pneumonia

    by Camila Cardoso, Antônio Felipe Silva Carvalho, Edvaldo S. Lara, Fernanda Silva Carneiro, Isabella Zaidan, Lais C Grossi, Ana Clara M. Montuori-Andrade, Jéssica A. M. Souza, Franciel B. Felix, Adelson H. A. Monteiro, et al.

    Accumulating evidence supports pro-resolving actions of the Plasminogen/Plasmin (Plg/Pla) system during inflammation, beyond its classical role in fibrin degradation. Here, we investigated the role of Plg/Pla on key features of inflammation resolution in a murine model of severe pneumococcal pneumonia. High levels of Plg were observed in the airways following infection, accompanied by increased levels of plasminogen activator inhibitor-1, neutrophil elastase and Plg degradation fragments as inflammation progressed. Pla treatment of mice infected with Streptococcus pneumoniae (Sp) decreased neutrophilic infiltration in airways and lungs, accompanied by lower concentrations of the neutrophil chemoattractive chemokines CXCL1 and CXCL2, as well as the pro-inflammatory cytokines TNF, IL-6, and IL-1β. Pla-treatment also enhanced neutrophil apoptosis and efferocytosis, and slightly reduced bacterial loads in bronchoalveolar lavage. In addition, Pla decreased damage and fibrin deposition in lungs, improving pneumonia-driven pulmonary mechanical dysfunction, and rescuing mice from lethality. Pla-induced resolution of Sp-evoked inflammation was associated with neutrophil apoptosis, as the caspase-3 specific inhibitor Z-DEVD-FMK blocked Pla protective actions. In addition to the effects on neutrophils, intranasal instillation of Pla in naïve mice increased the number of alveolar macrophages and guided them toward a regulatory phenotype marked by enhanced efferocytosis of apoptotic neutrophils and increased bacterial phagocytosis, ultimately promoting host protection against pneumococcus-induced inflammation and tissue damage. In sum, our findings demonstrate that plasmin modulates the lung inflammatory milieu and promotes key pro-resolving events, namely neutrophil apoptosis and expansion of alveolar macrophage with enhanced efferocytosis and phagocytic abilities, resulting in improved lung function and survival in pneumococcal pneumonia.


  • Annexin A1/FPR2 pathway modulates leukocyte function during Escherichia coli‐induced pneumonia to promote resolution of inflammation and restores lung function

    by Edvaldo S. Lara, Antônio Felipe S. Carvalho, Camila Cardoso, Isabella Zaidan, Laís C. Grossi, Fernanda S. Carneiro, Erick Bryan S. Lima, Adelson Heric A. Monteiro, Rodrigo S. Caixeta, Isabella L. Augusto, et al.

    Background and Purpose: Gram‐negative bacteria are the main causes of pneumonia in the nosocomial environment. Inflammation triggered during pneumonia is necessary for bacterial clearance but must be spatially and temporally regulated to prevent further tissue damage and bacterial dissemination. Emerging data shows that annexin A1 (ANXA1) signalling through its receptor FPR2 promotes host resistance and resilience in preclinical models of infectious disease.Experimental Approach: Using a mouse model of Escherichia coli‐induced pneumonia, the role of ANXA1/FPR2 on key steps of inflammation resolution was evaluated.Key Results: Anxa1 and Fpr2/3 knockout mice, intranasally infected with E. coli, exhibited exacerbated neutrophilic inflammation, higher bacterial dissemination, decreased neutrophil apoptosis/efferocytosis counts in the airways and higher levels of inflammatory cytokines/chemokines coupled to marked lung damage and dysfunction, as compared to WT mice. Treatment of WT‐infected mice with the ANXA1 peptidomimetic, annexin I‐(2‐26), decreased inflammation, increased apoptosis/efferocytosis of neutrophils and improved bacterial clearance in the airways and lungs, resulting in an improvement of lung function. The pan‐caspase inhibitor Z‐VAD‐FMK prevented annexin I‐(2‐26)‐induced resolution of the neutrophilic inflammation, underlining neutrophil apoptosis as the main mechanism for annexin I‐(2‐26) promotion of resolution of E. coli pneumonia. In addition, annexin I‐(2‐26) treatment increased the numbers of airway macrophages of infected mice and promoted macrophage phagocytosis of E. coli in vitro.Conclusions and Implications: In summary, these findings highlight the role for ANXA1/FPR2 pathway as a nonredundant resolution mechanism for E. coli‐induced pneumonia and demonstrate that annexin I‐(2‐26) as a potential host‐directed therapeutic approach to treat infectious lung diseases.


  • The angiotensin‐(1‐7)/ MasR axis improves pneumonia caused by Pseudomonas aeruginosa : Extending the therapeutic window for antibiotic therapy

    by Isabella Zaidan, Antônio Felipe Silva Carvalho, Laís C. Grossi, Jéssica A. M. Souza, Edvaldo S. Lara, Ana Clara M. Montuori‐Andrade, Camila Cardoso, Fernanda S. Carneiro, Erick Bryan de Sousa Lima, Adelson Héric Alves Monteiro, et al.

    Pseudomonas aeruginosa is a frequent cause of antimicrobial‐resistant hospital‐acquired pneumonia, especially in critically ill patients. Inflammation triggered by P. aeruginosa infection is necessary for bacterial clearance but must be spatially and temporally regulated to prevent further tissue damage and bacterial dissemination. Emerging data have shed light on the pro‐resolving actions of angiotensin‐(1‐7) [Ang‐(1‐7)] signaling through the G protein‐coupled receptor Mas (MasR) during infections. Herein, we investigated the role of the Ang‐(1‐7)/Mas axis in pneumonia caused by P. aeruginosa by using genetic and pharmacological approach and found that Mas receptor‐deficient animals developed a more severe form of pneumonia showing higher neutrophilic infiltration into the airways, bacterial load, cytokines, and chemokines production and more severe pulmonary damage. Conversely, treatment of pseudomonas‐infected mice with Ang‐(1‐7) was able to decrease neutrophilic infiltration in airways and lungs, local and systemic levels of pro‐inflammatory cytokines and chemokines, and increase the efferocytosis rates, mitigating lung damage/dysfunction caused by infection. Notably, the therapeutic association of Ang‐(1‐7) with antibiotics improved the survival rates of mice subjected to lethal inoculum of P. aeruginosa , extending the therapeutic window for imipenem. Mechanistically, Ang‐(1‐7) increased phagocytosis of bacteria by neutrophils and macrophages to accelerate pathogen clearance. Altogether, harnessing the Ang‐(1‐7) pathway during infection is a potential strategy for the development of host‐directed therapies to promote mechanisms of resistance and resilience to pneumonia.